Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study

Authors: Pérez-Garrigues, H.¹; Kuessner, D.²; Benecke, H.²

Source: Current Medical Research and Opinion, Volume 23, Number 11, November 2007 , pp. 2753-2761(9)

Buy & download fulltext article:

Price: $51.50 plus tax (Refund Policy)

Abstract:

Objectives and methods: OSVaLD (Observational Study in patients suffering from recurrent peripheral vestibular Vertigo to Assess the effect of betahistine 48 mg/day on quality of Life and Dizziness symptoms) is a 3-month, open-label, multi-national post-marketing surveillance study of betahistine 48 mg/day in the management of patients with vertigo of less than 5 years in duration. The aim of the study is to examine the burden of disease associated with vertigo, as determined by scores on the Dizziness Handicap Inventory (DHI), Short Form-36 (SF-36) questionnaire and the Hospital Anxiety and Depression Scale (HADS). Changes in DHI, SF-36 and HADS scores between baseline and 3 months are used to assess the therapeutic effects of betahistine.

Results: Participants (n = 2037) have been recruited from 13 countries in four continents (North and South America, Asia and Europe), representing a wide range of cultural and linguistic traditions. Approximately two-thirds of the patients are women. Sixty per cent of patients have diagnoses of peripheral vestibular vertigo of unknown pathology or benign paroxysmal positional vertigo; 13% have a diagnosis of Ménière's disease. All three of the instruments used characterize this as a population with extensive vertigo-attributable morbidity at baseline. The mean DHI score of the population is 63.7 ± 15.7 (DHI scale: 0 = no handicap; 100 = major self-perceived handicap), SF-36 scores in all domains are below the population average for the USA and the HADS indicated that > 50% of patients exhibit symptoms of anxiety or depression or both, including 9% who have severe manifestations of either or both conditions.

Conclusions: This report describes the design and implementation of OSVaLD and presents baseline demographic and clinical features of the patients. Full results of the study, anticipated in 2007, will provide more details about the manifestations of vertigo in routine practice and the response to betahistine.

Keywords: BETAHISTINE; BURDEN OF DISEASE; DHI SCORE; HADS SCORE; HRQOL; SF-36; VERTIGO, VESTIBULAR

Document Type: Case report

DOI: http://dx.doi.org/10.1185/03007X233016

Affiliations: 1: Otorhinolaryngology Department, Hospital Universitario La Fe, Valencia, Spain 2: Solvay Pharmaceuticals, Hannover, Germany

Publication date: 2007-11-01

More about this publication?